BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2025

View Archived Issues
Illustration of anatomy of a human embryo at 7 weeks

CRVBC: Cardiac diseases can start in utero after immune migration

A healthy life for a healthy heart is a popular saying. However, even when following good habits, heart health can be already compromised from the very earliest stages of development. Maternal cells reach the embryo through the placenta contributing to its normal formation. So, just as the mother helps form a functional heart, she can also induce a condition that may not appear until adulthood. Read More
Molecule illustration

Unnatural Products joins Argenx in a $1.5B macrocyclic deal

Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and R&D funding, could end up with about $1.5 billion in milestones and options payments plus tiered royalties on net sales. Read More
Illustration of dividing cancer cells

Dual-action anti-CD47 fusion protein has reduced hematotoxicity

Researchers at Caedo Oncology AS and collaborators have recently developed a new chimeric bifunctional anti-CD47 (IgG4) fusion protein, CO-001, and its optimized variant CO-005, a bivalent humanized single-chain fragment variable-fragment crystallizable fusion protein, which exhibited potent anti-cancer activity through a dual mechanism of action. Read More
Nervous system illustration

Redox-sensitive PET tracer detects ROS-driven neuroinflammation

Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter probe for imaging neuroinflammation in preclinical models of multiple sclerosis (MS). MS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by inflammatory cell infiltration, demyelination and axonal damage. Read More

Hungarian scientists patent new potassium channel blockers

Researchers at Semmelweis University and University of Szeged have disclosed aminoalkylated benzoxy compounds acting as potassium channel blockers reported to be useful for the treatment of atrial fibrillation and ventricular arrhythmia. Read More
Acute myeloid leukemia

Taming TIGAR prevents antitumor T-cell dysfunction

In a study published recently in Cancer Immunology, Immunotherapy journal, researchers from Jiangsu Province Hospital and colleagues investigated the impact of targeting the TP53-induced glycolysis and apoptosis regulator (TIGAR) on T-cell function and antitumor immunity in acute myeloid leukemia. Read More
Cell research illustration

Immune checkpoint enhancer ALTB-268 decreases inflammation

Agonists of immune checkpoint modulators for treating autoimmune and inflammatory disorders have shown high potential in immunotherapy. P-selectin glycoprotein ligand 1 (PSGL-1) is known to exert immune checkpoint regulator functions in T cells aside from its classic role as an adhesion molecule involved in leukocyte trafficking. Read More

Euregen Biopharma divulges new Mat2A inhibitors

Euregen Biopharma Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer. Read More

Kestrel Therapeutics describes new GTPase KRAS inhibitors

Kestrel Therapeutics Inc. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer. Read More
Feet on scale and measuring tape

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity

Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity. Read More

New GPR40 agonists disclosed in Cascade Pharmaceuticals patent

Cascade Pharmaceuticals Inc. has divulged free fatty acid receptor 1 (FFAR1; GPR40) agonists reported to be useful for the treatment of diabetes. Read More

Pfizer discovers new KAT2A and KAT2B inhibitors

Pfizer Inc. has described acetyltransferase KAT2A and/or KAT2B inhibitors reported to be useful for the treatment of cancer. Read More
Woman measuring her body fat with caliper

ASC-47 shows superior weight loss effect compared to semaglutide

ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in healthy subjects and in patients with obesity, respectively. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing